


In partnership with



Alzheimer's
Drug Discovery
Foundation

Alzheimer's: The Puzzle, The Partners, The Path Forward



October 23, 2013

The National Academy of Sciences Building
2101 Constitution Ave., N.W.
Washington, DC 20037

Alzheimer's Disease (AD) is a debilitating neurodegenerative disease that currently afflicts more than 5 million people in the U.S. In an effort to catalyze progress in AD innovation and R&D, PhRMA, in partnership with the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation, is hosting an all-day forum to convene top industry and academic scientists, patients, policymakers, and other stakeholders. Key topics of focus will include how to accelerate the impact of pre-competitive collaborative efforts and exploring challenges in clinical trials recruitment unique to Alzheimer's.

AGENDA

8:00 am - 9:00 am

Registration and Continental Breakfast

9:00 am - 9:20 am

Opening Remarks

Bill Chin, MD, Executive Vice President, Scientific & Regulatory Affairs, PhRMA

Tim Garnett, MD, Chief Medical Officer and Senior Vice President, Development Center of Excellence, Eli Lilly

9:20 am - 10:20 am

Keynote Address

Permanent Present Tense:

The Unforgettable Life of the Amnesic Patient, H.M.

Suzanne Corkin, PhD, Professor of Behavioral Neuroscience, Emerita, Massachusetts Institute of Technology



10:20 am - 10:30 am

Coffee Break

AGENDA

<p>10:30 am - 12:15 pm</p>	<p>Pre-Competitive Partnerships To maximize collaborative efforts that would progress Alzheimer’s disease R&D, there is a need to examine public-private partnerships in the pre-competitive space. This panel will explore research areas presenting the greatest opportunities for future collaborations.</p> <p>*Moderator: Paul Aisen, MD, <i>Director, Alzheimer’s Disease Cooperative Study Professor, Department of Neurosciences, UCSD</i> John Wilbanks, <i>Chief Commons Officer, Sage Bionetworks</i> Stevin Zorn, PhD, <i>Executive Vice President Research & Development, Lundbeck</i> Diane Stephenson, PhD, <i>Executive Director, Coalition Against Major Diseases, C-Path</i> Howard Fillit, MD, <i>Executive Director and Chief Science Officer, Alzheimer’s Drug Discovery Foundation</i> Neil Buckholtz, <i>Director, Division of Neuroscience, National Institute on Aging, NIH</i> David Wholley, <i>Director, The Biomarkers Consortium, Foundation for the National Institutes of Health</i></p>
<p>12:15 pm - 1:45 pm</p>	<p>Lunch Stories from the Frontlines</p> <p><i>Sponsored by the Alzheimer’s Association</i></p>
<p>2:00 pm - 3:45 pm</p>	<p>Pre-Symptomatic Clinical Trials There are several significant challenges in the clinical development of AD therapeutics, particularly as the focus shifts to earlier stages of the disease. This panel will discuss important discoveries that helped elucidate the clinical heterogeneity of the disease and the subsequent challenges in the use and adoption of clinical and functional endpoints in new clinical trial design.</p> <p>Moderator: Alice Park, <i>Health and medicine writer, TIME</i> Andrew Satlin, MD, <i>Executive Vice President, Eisai</i> Nicholas Kozauer, MD, <i>Clinical Team Leader, Division of Neurology Products, FDA</i> Paul Aisen, MD, <i>Director, Alzheimer’s Disease Cooperative Study Professor, Department of Neurosciences, UCSD</i> Reed Tuckson, MD, <i>Managing Director, Tuckson Health Connections and Former EVP and Chief of Medical Affairs, UnitedHealth Group</i> Neill Graff-Radford, MD, <i>Neurologist, Mayo Clinic</i> Heather Snyder, PhD, <i>Director of Medical and Scientific Operations, Alzheimer’s Association</i></p>
<p>3:45 pm - 3:55 pm</p>	<p>Alzheimer’s: The Path to 2025 George Vradenburg, JD, <i>Convener of Global CEO initiative on Alzheimer’s and Chairman and Co-Founder, USAgainstAlzheimer’s</i></p>
<p>3:55 pm - 4:30 pm</p>	<p>The Path Forward for Science and Policy Robert Egge, <i>Vice President Policy, Alzheimer’s Association</i> Howard Fillit, MD, <i>Executive Director and Chief Science Officer, Alzheimer’s Drug Discovery Foundation</i></p>
<p>4:30 pm - 4:35 pm</p>	<p>Concluding Remarks Bill Chin, MD, <i>Executive Vice President, Scientific & Regulatory Affairs, PhRMA</i></p>
<p>4:45 pm- 5:45 pm</p>	<p>Reception</p>